Enoblituzumab (MGA271)

enoblituzumab · MacroGenics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Enoblituzumab (MGA271), covering 2021-08-24 to 2021-08-24. Get the full timeline:

Most recent: Clinical Trial Update: Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer [Phase 2]